Table 3.
Negativization rate of initially seropositive AE patients following treatment (last serum available after start of treatment) (CI95%).
| AE-group (group size) |
no. of initially EgHF-positives | no. of EgHF-negatives at the end | % EgHF negativization (CI95%) |
no. of initially Em2-positives | no. of Em2-negatives at the end | % Em2 negativization (CI95%) |
no. of initially recEm18-positives | no. of recEm18-negatives at the end | % recEm18 negativization (CI95%) |
|---|---|---|---|---|---|---|---|---|---|
| A (n = 45) |
43 | 21 | 49% (33–64%) |
38 | 18 | 47% (31–64%) |
33 | 25 | 76% (58–89%) |
| B (n = 11) |
10 | 3 | 30% (7–65%) |
11 | 4 | 36% (11–69%) |
10 | 4 | 40% (12–74%) |
| C (n = 20) |
20 | 4 | 20% (6–44%) |
18 | 2 | 11% (1–35%) |
18 | 4 | 22% (6–48%) |
| D (n = 11) |
9 | 3 | 33% (8–70%) |
7 | 4 | 57% (18–90%) |
8 | 6 | 75% (35–97%) |
| E (n = 4) |
4 | 0 | 0/4 (0–60%) |
4 | 1 | 1/4 (1–81%) |
4 | 2 | 2/4 (7–93%) |
| A-E (n = 91) |
86 | 31 | 36% | 78 | 29 | 37% | 73 | 41 | 56% |